Furthermore, Hsiao and colleagues determined that exogenous combination IFN-γ and IL-6 therapy could increase the expression of MHC class I and II molecules on tumor cells, potentially enhancing the ability of T cells to recognize and target cancer cells [62]. This evidence concerns the gene IL6 and cancer.